Posted by Michael Wonder on 11 Oct 2022
JW Therapeutics announces NMPA approval of relmacabtagene autoleucel injection in patients with relapsed or refractory follicular lymphoma
11 October 2022 - JW Therapeutics announced that the NMPA of China has approved the supplemental new drug application for its anti-CD19 autologous chimeric antigen receptor T cell immunotherapy product relmacabtagene autoleucel injection (Carteyva) for the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment.
This is the second approved indication for relmacabtagene autoleucel following its initial approval and launch in September last year, and makes it the first cell immunotherapy product approved in China for the treatment of patients with relapsed/refractory follicular lymphoma.
